LEXINGTON, Mass.--(BUSINESS WIRE)--EPIX Pharmaceuticals, Inc. (NASDAQ: EPIX) announced today that it has initiated a Phase 2b clinical trial to evaluate the efficacy of PRX-00023, a selective 5-HT1A partial agonist, in patients with a primary diagnosis of major depressive disorder (MDD) who also have concurrent anxiety. Data from this trial are expected in the first half of 2008.
